EBITDA

As Revvity execs prepare for key conferences, investors will watch for clues on AI strategy, growth guidance, and margin recovery after a mixed 2025.

A new supply agreement for the rare isotope Actinium-225 between NorthStar and BIOEMTECH promises to break a critical bottleneck in radiopharmaceutical R&D.

The confidential sale of Louisiana's iconic Cypress Cove Marina & Lodge signals a hot market for niche real estate, where big money moves behind closed doors.

New research reveals a startling link between AI's excessive permissions and a surge in security breaches, forcing a rethink of enterprise trust and access.

Generali Global Assistance consolidates its US and Canadian operations under new leadership, aiming for dominance in a booming post-pandemic travel market.

A new series from A3 and BBC StoryWorks moves beyond efficiency to show how automation is augmenting human lives in healthcare, education, and more.

SaaS veteran Alison Forsythe takes the helm at Intellinetics, tasked with turning heavy investment into profitable growth in the booming digital transformation market.

At a key conference, DocGo's CEO will navigate financial headwinds while promoting a vision for proactive, tech-enabled healthcare delivery.

Fresh off its IPO, Lumexa Imaging's leadership heads to key conferences. Here’s what’s at stake as they pitch their growth strategy to investors.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

TMD Energy's new director, a capital markets expert, sparks a 6.6% stock gain and speculation of M&A or major fundraising on the horizon.

Glean's new AI assistant promises to move beyond search to autonomous action, tackling enterprise AI adoption challenges with deep contextual understanding.

Neurotech leader BrainsWay adjusts its share structure in a move to enhance liquidity, clarify valuation, and attract a broader base of global investors.

An Indiana firm's implantable pump gains key FDA status, promising a future with less mental burden for Type 1 Diabetes patients. But the road is long.

Cronos Group enters the premium vape race with its new 'liquid diamonds' PUFFERZ, facing immediate competition in Canada's booming all-in-one market.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

Ceva's AI licensing revenue soared in 2025, securing deals with a top PC OEM and Microchip, signaling a major industry shift to on-device intelligence.

With 23,000 metres of drilling, Copper Giant aims to unlock one of the world's largest undeveloped copper caches, vital for the energy transition.

Ahead of its March 3 earnings call, 908 Devices' strong preliminary results and focus on handheld tech signal a pivotal year for the security innovator.

A new report reveals why some indie restaurants thrive while others struggle, and it’s not just hard work. It's about access to strategic tools.